The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
Steady: 0 in the last 7 days
Updated sep 19
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Central government utilizes the Department of Pharmaceuticals (DoP) for market oversight, discussing systematic price reconciliation via DPCO, as the FDA flags price gaps between trade and MRPs.Sub-event
FDA is monitoring drug industry practices and pricing, utilizing JAMA studies.1 source
State drug regulator found pricing anomalies in drug manufacturers' sales.1 source
Keep exploring
The entities involved
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- A physician in Houston wrote about the current state and trends within the drug market.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.